{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-24-000006","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.782276+00:00","generated_at":"2026-06-04T07:01:01.090209+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Altimmune reports Q4 net loss $31.6M; positive pemvidutide body composition data; HepTcell discontinued","bullets":["Net loss $31.6M ($0.54/share) for Q4 2023, including $12.4M impairment for discontinued HepTcell program.","Cash $198.0M; body composition: 74.5% weight loss from fat, 25.5% from lean mass on pemvidutide.","MOMENTUM: 15.6% mean weight loss at 48 weeks on 2.4 mg pemvidutide; >30% achieved ≥20% weight loss.","IMPACT Phase 2b MASH trial enrollment ongoing; topline 24-week data expected Q1 2025.","HepTcell development stopped; overall response in Phase 2 insufficient to warrant further advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-24-000006","json":"https://secwatch.observer/filing/0001326190-24-000006.json","markdown":"https://secwatch.observer/filing/0001326190-24-000006.md","text":"https://secwatch.observer/filing/0001326190-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/0001326190-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/alt-20240327x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:01:01.090209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6c40835495a27fbc99ded990084061f659d87cf","claim":"Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year and fiscal quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/0001326190-24-000006-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}